




Herma Heart Institute



UPDATE: Risk Stratification and Management of Hereditary Thoracic Aortic Aneurysms

Salil Ginde, MD, MPH

Director, Marfan and Related Connective Tissue Disorder Program
Children's Wisconsin and Froedtert Hospital
Medical College of Wisconsin



Objectives

- Discuss new insights into the genetic basis of hereditary thoracic aortic disease
- Utilizing both genetic testing and imaging to guide medical and surgical management


Disclosures Dr. Salil Ginde

I have no relevant financial disclosures

Aortic Aneurysms



Aortic dissection



Thoracic aortic aneurysm prevalence = 1%

Type A Dissection

- 50% mortality before hospital admission
- 1-2% of all deaths in Western countries

Causes of Aortic Aneurysms

- Hypertension and/or atherosclerosis
- Inflammatory conditions
- Traumatic injury
- Genetic conditions (inherited disorder of connective tissue)
≈ 20-25% of cases

Characterizing the Young Patient With Aortic Dissection: Results From the International Registry of Aortic Dissection (IRAD)


Table 1. Baseline Demographics of Patients in the International Registry of Aortic Dissection Based on Age Categories of <40 and ≥ 40 Years of Age

Variables	Age <40 n = 68 (%)	Age ≥ 40 n = 883 (%)	p Value
Age, yrs (mean \pm SD)	30.7 ± 6.6	63.9 ± 11.5	NA
Type of dissection			NS
Type A	46 (68)	574 (65)	
Type B	22 (32)	309 (35)	
Male gender	52 (76)	596 (67)	NS
White race	55 (81)	699 (79)	NS
Diabetes	0 (0)	38 (4)	NS
Hypertension	23 (34)	635 (72)	<0.001
Atherosclerosis	1 (1)	267 (30)	<0.001
Marfan syndrome	34 (50)	19 (2)	<0.001
Prior aortic valve disease	7 (10)	74 (8)	NS
Bicuspid aortic valve (n = 516)	6 (9)	12 (1)	<0.001
Known aortic aneurysm	13 (19)	115 (13)	NS
Prior aortic dissection	5 (7)	50 (6)	NS


Conditions Predisposing to Thoracic Aneurysms

- Syndromic Disorders (several non-cardiac features)
 - Marfan Syndrome
 - Loeys-Dietz Syndrome
 - Vascular Ehlers-Danlos Syndrome
 - Autosomal Dominant Polycystic Kidney Disease
 - Turner Syndrome
- Non-syndromic Disorders (near-normal phenotype)
 - Bicuspid aortic valve
 - Familial Thoracic Aortic Aneurysm/Dissection
 - Variants of Loeys-Dietz Syndrome

Extracellular Matrix



TGF β signaling



Smooth muscle cell contractile apparatus






Figure 2 | Signalling pathways involved in familial thoracic aortic aneurysms (TAA). The proteins encoded by genes in which mutations cause familial TAA are indicated with a green asterisk. **a** | Mechanical stimuli activate

Marfan Syndrome


- Autosomal dominant mutation in gene coding for fibrillin -1 (FBN1)
- Three organ systems are the most affected:
 - Musculoskeletal system (pectus, scoliosis)
 - Eye (lens dislocation)
 - Aneurysms/Dissection, Mitral valve prolapse

* High degree of clinical variability




MARFAN SYNDROME

- Autosomal dominant mutation in gene coding for fibrillin 1 (FBN-1)
- Extracellular matrix protein
 - ◆ Major component of microfibrils associated with elastin fibers
 - ◆ Elastin fibers
 - ◆ Function in mediating elastic recoil of tissues



Structural role of Fibrillin-1



Marfan Syndrome - Outcomes



Aortic dissection

- Aortic complications (dissection, rupture) most common causes of death
- Average life expectancy
 - In 1972 – 45 years¹
 - In 1995 – 72 years (similar to general population)²

¹Murdoch et al. N Engl J Med 1972

²Silverman et al. Am J Cardiol 1995

Management of Aortic Aneurysms

Goals

1. Slow the growth of the aneurysm overtime
 - a) Medications
 - b) Restrictions to vigorous physical activity
2. Preventative surgery before aortic dissection

PROGRESSION OF AORTIC DILATATION AND THE BENEFIT OF LONG-TERM β -ADRENERGIC BLOCKADE IN MARFAN'S SYNDROME


JENNIFER SHORES, M.D., KENNETH R. BERGER, M.D., PH.D., EDMOND A. MURPHY, M.D., Sc.D.,
AND REED E. PYERITZ, M.D., PH.D.

- 1994
- 70 teen and adult pts with Marfan syndrome
 - 32 given propranolol
 - 38 given placebo
- Followed for up to 10 years


PROGRESSION OF AORTIC DILATATION AND THE BENEFIT OF LONG-TERM β -ADRENERGIC BLOCKADE IN MARFAN'S SYNDROME

JENNIFER SHORES, M.D., KENNETH R. BERGER, M.D., PH.D., EDMOND A. MURPHY, M.D., Sc.D.,
AND REED E. PYERITZ, M.D., PH.D.

Slowed rate of aortic dilation



Lowered risk for aortic complications




Beta-blockers and Marfan Syndrome

- Beta blockers became primary medication to slow growth of aortic aneurysms
- Subsequent studies showed that majority of patients on beta-blockers
 1. still had progression of aneurysm
 2. at risk for aortic dissection and/or needed heart surgery.

Marfan Mouse Model



- 2003
- Harry Dietz, MD
- Created FBN1+/- Marfan syndrome mouse mouse model (FBN1+/-)
- Fibrillin has more than a structural role




Functional role of Fibrillin-1

Mouse model showed that:


- Fibrillin-1 regulates a growth factor - TGF- β
- Mice had $\uparrow\uparrow$ TGF- β

Regulates cellular function
Cell proliferation
Cell cycle arrest
Cell apoptosis
Cell differentiation
Extracellular formation

Losartan



Losartan in Marfan Mouse



Marfan syndrome

Fibrillin gene mutation



Losartan

Beta blockers

LORSARTAN vs. BETA-BLOCKERS

(fibrillin protein, connective tissue)

(blood pressure, heart rate)



Aortic Aneurysm

The NEW ENGLAND JOURNAL *of* MEDICINE

ESTABLISHED IN 1812


NOVEMBER 27, 2014


VOL. 371 NO. 22

Atenolol versus Losartan in Children and Young Adults with Marfan's Syndrome

- 21 centers through Pediatric Heart Network
- 608 Marfan syndrome patients (6 months to 25 years old)
 - 303 received atenolol
 - 305 received losartan
- Followed with echocardiograms for 3 years

A






Recommendations for Medical Management

- After Marfan syndrome diagnosed, start either beta-blocker or ARB (losartan or irbesartan)
- Monitor with echocardiogram +/- CT or MRI at least every year
- If aneurysm grows on single therapy, then add a second medication

Extracellular Matrix



TGF β signaling




Figure 2 | Signalling pathways involved in familial thoracic aortic aneurysms (TAA). The proteins encoded by genes in which mutations cause familial TAA are indicated with a green asterisk. **a** | Mechanical stimuli activate



Loeys Dietz Syndrome – Discriminating Features


HEAD AND NECK:

Head Craniosynostosis
Eye No lens dislocation
Face Malar hypoplasia / Micrognathia / Retrognathia
Eyes Hypertelorism / Exotropia / Blue sclerae / Proptosis
Mouth Bifid uvula / Cleft palate (uncommon)



CARDIOVASCULAR:

Aortic dissection at smaller dimensions (>4.5 cm)
Arterial tortuosity, generalized
Cerebral aneurysm



SKELETAL: Joint laxity

FEET **Talipes equinovarus (club foot)**



SKIN **Velvety texture / Translucent skin**

NEUROLOGIC:

Chiari malformation
Hydrocephalus
DD/MR

2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease

A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine

Criteria for Prophylactic Aortic Root Replacement:

- Marfan syndrome = 5.0 cm
- Loeys-Dietz syndrome = 4.5 cm


Loeys-Dietz Syndrome

Genetic Variant	Aortic Event	Age at Aortic Event	Aneurysm Repair/Dissect	Type A/Type B Dissection	Aortic size at time of Dissection
TGFB1	39%	28 yrs (12-72)	50%/50%	91%/9%	58.3 mm
TGFB2	44%	35 yrs (8-85)	54%/46%	69%/31%	51.4 mm
SMAD3	37%	47 yrs (25-77)	30%/70%	76%/13%	54 mm
TGFB2	21%	35 yrs (31-60)	50%/50%	N/A	52 mm


Jondeau, et al. Circ Cardiovasc Genet 2016
 Hostetler, et al. J Med Genet 2019
 Boileau, et al. Nat Genet 2021

Gender Differences in Age of Aortic Events

TGFBR1 mutation



TGFBR2 mutation




Loeys-Dietz Syndrome: Dissections < 4.5 cm


- TGFBR 1 and 2 (6 patients)
 - Female
 - Aortic tortuosity
 - Hypertelorism
 - Wide scars
- SMAD3 (3 patients)
 - HTN
 - History of smoking

Jondeau, et al. Circ Cardiovasc Genet 2016
Hostetler, et al. J Med Genet 2019

Extracellular Matrix



TGF β signaling



Smooth muscle cell contractile apparatus







Figure 2 | Signalling pathways involved in familial thoracic aortic aneurysms (TAA). The proteins encoded by genes in which mutations cause familial TAA are indicated with a green asterisk. **a** | Mechanical stimuli activate

Nonsyndromic Hereditary Thoracic Aortic Disease



- Autosomal dominant inheritance
- Decreased penetrance, variable expression
- Minimal systemic features
- 20% of pts have a first-degree relative w/ TAAD
- Caused by genetic variants that disrupt a protein in SMC contractile unit and alter smooth muscle cell force generation



Smooth Muscle Cell Contraction





ACTA2-Associated Aortic Disease




Median Age at Aortic Event = 36 y/o
33% Dissected at Dimension < 5.0 cm

ACTA2-Associated Aortic Disease




ACTA2-Associated Aortic Disease



R149 and R118


- Predispose to early onset coronary artery disease

Smooth Muscle Cell Contraction




MYLK-Associated Aortic Events

Overall Risk



Missense vs. Null Variants



Gene Mutations

Disruption of SMC contractile function due to disruption of a component of the mechanotransduction complex *ACTA2*, *MYH11*, *FLNA*, *FBN1*

Increased vascular wall pressures

HTN or weight lifting

β-adrenergic blocking agents (atenolol, propanolol)

SMC contractile dysfunction /overload

Activation of stress pathways in SMCs leading to expression of mitotic and trophic factors, such as IGF-1, TGF- β 1, MIP-1 α and β .


Activation of tissue RAS (?)

Activation of stretch pathways in SMCs leading to increased MMPs and proteoglycans

AT1 receptor blocking agents (losartan)




Degradation of elastic fibers
Accumulation of proteoglycans
Increased vascular volume in vasa vasorum

Gene-based Timing of Prophylactic ARR




Aortic Root Replacement

Composite Mechanical Valve



HHI/MCW Valve-sparing ARR Outcomes



HHI/MCW Aortopathy Clinic

Indications for Referral

- Systemic features of connective tissue disorder (i.e. pectus, scoliosis, wrist/thumb sign, cleft palate, club feet, etc.)
- Family history of thoracic aneurysms or dissections
- Aortic dissection < 60 years of age
- Ascending aortic aneurysm diagnosed < 50-60 years of age

HHI/MCW Aortopathy Clinic

1. Patient/family evaluated by Cardiology & Genetics (Med-Peds providers)
2. Custom HTAD gene panel (> 20 genes)

- If positive genetic testing (\approx 20-30%) \rightarrow Gene-specific management
 - Medical therapy (beta-blocker or ARB), activity restrictions
 - Surveillance imaging (+/- head/neck imaging)
 - Timing of aortic aneurysm repair
- If negative testing or variant of unknown significance (\approx 70-80%)
 - Imaging of first-degree relatives
 - Whole Exome Sequencing

Summary

- Evolving understanding of how genetic variants result in hereditary thoracic aortic disease
- Identifying causative HTAD genetic variant critical for:
 - Screening for aortic and vascular complications
 - Guide medical and surgical management
 - Identifying at-risk family members

Thank You



Salil Ginde, MD
Phone: 414-266-4757
Email: sginde@mcw.edu

